Zacks4g fa · leggi qui →
Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…
StockStory6g fa · leggi qui →
1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.…
StockStory11g fa · leggi qui →
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and over the past …
StockStory19g fa · leggi qui →
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a hig…
Zacks31g fa · leggi qui →
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.…
StockStory34g fa · leggi qui →
3 Reasons HAE is Risky and 1 Stock to Buy Instead
Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This might have investors contemplating their…
StockStory38g fa · leggi qui →
3 Profitable Stocks We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my…
Simply Wall St.55g fa · leggi qui →
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment
Haemonetics (HAE) has redrawn its business map by merging its Plasma and Blood Center units into a single Apheresis segment and renaming its Hospital segment as MedSurg, aligning reporting with how ma…
MT Newswires59g fa · leggi qui →
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the…
Simply Wall St.70g fa · leggi qui →
Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next
Earlier this week, Haemonetics reported quarterly results that surpassed analyst expectations for both revenue and earnings, supported by solid demand in its plasma and hospital-focused product lines.…